Literature DB >> 72667

57-cobalt-bleomycin as a tumor scanning agent in primary hepatocellular cancer.

M Kew, J Allen, J Levin.   

Abstract

57Co-bleomycin and 99mTc-sulfur colloid scans were performed in 13 southern African black patients with primary hepatocellular cancer (PHC) and 3 patients with other space-occupying hepatic lesions. Selective concentration of 57Co-bleomycin in the defect or defects seen on the 99mTc-sulfur colloid scan occurred in only 4 of the 13 (31%) patients with PHC. In the remaining PHC patients, as well as in the 2 patients with metastatic liver disease and the 1 patient with an amebic liver abscess, the 57 Co-bleomycin and 99mTc-sulfur colloid scans were identical. 57Co-bleomycin appears to have only a limited place as a tumor-seeking agent in the diagnosis of PHC in southern African blacks.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 72667     DOI: 10.1007/BF00252171

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  9 in total

1.  Clinical evaluation of tumor scanning with 57Co-bleomycin.

Authors:  Y Suzuki; K Hisada; T Hiraki; A Ando
Journal:  Radiology       Date:  1974-10       Impact factor: 11.105

2.  False-negative 75Se-selenomethionine scans in primary liver cancer.

Authors:  M C Kew; E W Geddes; J Levin
Journal:  J Nucl Med       Date:  1974-04       Impact factor: 10.057

3.  On the mechanism of action of bleomycin. Strand scission of DNA caused by bleomycin and its binding to DNA in vitro.

Authors:  H Suzuki; K Nagai; E Akutsu; H Yamaki; N Tanaka
Journal:  J Antibiot (Tokyo)       Date:  1970-10       Impact factor: 2.649

4.  Cobalt-labeled bleomycin--a new radiopharmaceutical for tumor localization. A comparative clinical evaluation with gallium citrate.

Authors:  K P Poulose; A E Watkins; R C Reba; W C Eckelman; M Goodyear
Journal:  J Nucl Med       Date:  1975-09       Impact factor: 10.057

5.  Some experience with 57Co-labeled bleomycin as a tumor-seeking agent.

Authors:  J J Rasker; A M Poll; H Beekhuis; M G Woldring; H O Nieweg
Journal:  J Nucl Med       Date:  1975-11       Impact factor: 10.057

6.  Chemical and biologic properties of isolated radiolabeled bleomycin preparations.

Authors:  W C Eckelman; W J Rzeszotarski; B A Siegel; H Kubota; M Chelliah; J Stevenson; R C Rebra
Journal:  J Nucl Med       Date:  1975-11       Impact factor: 10.057

7.  Gallium-67-citrate scanning in primary cancer of the liver: diagnostic value in the presence of cirrhosis and relation to alpha-fetoprotein.

Authors:  J Levin; M C Kew
Journal:  J Nucl Med       Date:  1975-10       Impact factor: 10.057

8.  Clinical evaluation of radiolabeled bleomycin (BLEO) for tumor detection.

Authors:  R B Grove; R C Reba; W C Eckelman; M Goodyear
Journal:  J Nucl Med       Date:  1974-06       Impact factor: 10.057

9.  Cancer incidence in the Bantu and "Cape Colored" races of South Africa: report of a cancer survey in the Transvaal (1953-55).

Authors:  J HIGGINSON; A G OETTLE
Journal:  J Natl Cancer Inst       Date:  1960-03       Impact factor: 13.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.